 100 patients with Breakthrough pain will be allocated to receive either oral prioxicam OP n50 or sublingual fentanyl SLF n50 . Patients will be divided randomly into two equal groups: oral prioxicam OP Group and sublingual fentanyl citrate SLF Group, comprising of 50 patients each. 